IP Library Granted Patent US 8,487,000
Granted Patent B2
US 8,487,000 · App. 11/005,449 · Granted Jul 16, 2013

Compound for the treatment of metabolic disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,487,000
App. No.
11/005,449
Granted
Jul 16, 2013
Kind
B2
Abstract

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Claims (82)

1. A compound of the formula:

wherein

n is 1 or 2;

q is 0 or 1;

t is 0 or 1;

R 5 is alkyl having from 1 to 3 carbon atoms;

m is 1;

X is —CH 2 — and R 1 is ethyl, and

A is phenyl, substituted by 1 or 2 groups selected from: fluoro, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or

m is 0 or 1,

X is —CH 2 CH 2 — and R 1 is hydrogen or alkyl having from 1 to 7 carbon atoms, and

A is phenyl, substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy,

or when R 1 is hydrogen, a pharmaceutically acceptable salt of the compound; or

m is 0 or 1,

X is —CH 2 CH(NHAc)— and R 1 is hydrogen or alkyl having from 1 to 7 carbon atoms, and

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy,

or when R 1 is hydrogen, a pharmaceutically acceptable salt of the compound.

2. The compound or salt of claim 1 , wherein R 1 is hydrogen or ethyl.

3. The compound or salt of claim 1 , wherein q is 0.

4. The compound or salt of claim 1 , wherein X is —CH 2 CH 2 —.

5. The compound or salt of claim 1 , wherein A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy;

wherein each halo is independently fluoro or chloro.

6. The compound or salt of claim 5 , wherein each halo substituent on phenyl ring A is fluoro.

7. The compound or salt of claim 6 , wherein phenyl ring A is substituted by 2 fluoro groups.

8. The compound or salt of claim 1 , wherein A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 carbon atom, perfluoromethyl, alkoxy having 1 carbon atom, and perfluoromethoxy.

9. A compound having the formula:

wherein

n is 1 or 2;

m is 0 or 1;

q is 0 or 1;

t is 0 or 1;

R 5 is alkyl having from 1 to 3 carbon atoms; and

X is —CH 2 — and R 1 is ethyl, and

one of R 2 and R 3 is selected from fluoro, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy, and the other is selected from hydrogen, halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or

X is —CH 2 CH 2 — and R 1 is hydrogen or alkyl having from 1 to 7 carbon atoms, and

one of R 2 and R 3 is selected from hydrogen, halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy, and the other is selected from halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy,

or when R 1 is hydrogen, a pharmaceutically acceptable salt of the compound; or

X is —CH 2 CH(NHAc)— and R 1 is hydrogen or alkyl having from 1 to 7 carbon atoms, and

R 2 and R 3 are each independently selected from hydrogen, halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy,

or when R 1 is hydrogen, a pharmaceutically acceptable salt of the compound.

10. The compound or salt of claim 9 , wherein R 1 is hydrogen or ethyl.

11. The compound or salt of claim 10 , wherein the compound is 4-[4-(2-(N-(2-fluorobenzyl)-N-methylamino)ethoxy)phenyl)]-4-oxobutyric acid.

12. The compound or salt of claim 10 , wherein the compound is (2RS)2-(N-acetyl)-4-(4-(2,6-difluorobenzyloxy)phenyl)-4-oxobutyric acid.

13. The compound or salt of claim 10 , wherein the compound is 4-(3-(4-trifluoromethylbenzyloxy)phenyl)-4-oxobutyric acid.

14. The compound of claim 9 , having the formula:

wherein

n is 1 or 2;

m is 0 or 1;

p is 1 and R 1 is ethyl, and

one of R 2 and R 3 is selected from fluoro, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy, and the other is selected from hydrogen, halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or

p is 2 and R 1 is hydrogen or alkyl having from 1 to 7 carbon atoms, and

one of R 2 and R 3 is selected from hydrogen, halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy, and the other is selected from halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy,

or when R 1 is hydrogen, a pharmaceutically acceptable salt of the compound.

15. The compound or salt of claim 14 , wherein R 1 is hydrogen or ethyl.

16. The compound or salt of claim 15 , wherein the compound is 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid.

17. The compound or salt of claim 14 , wherein one of R 2 and R 3 is hydrogen or halo and the other is halo.

18. The compound or salt of claim 17 , wherein the compound is 4-(4-(3-fluorobenzyloxy)phenyl)-4-oxobutyric acid.

19. The compound or salt of claim 17 , wherein the compound is 4-(4-(4-fluorobenzyloxy)phenyl)-4-oxobutyric acid.

20. The compound or salt of claim 17 , wherein the compound is 4-(4-(2-chlorobenzyloxy)phenyl)-4-oxobutyric acid.

21. The compound or salt of claim 17 , wherein R 2 is fluoro and R 3 is hydrogen.

22. The compound or salt of claim 21 , wherein the compound is 4-(4-(2-fluorobenzyloxy)phenyl)-4-oxobutyric acid.

23. The compound or salt of claim 21 , wherein the compound is 4-(4-(2-(2-fluorophenyl)ethoxy)phenyl)-4-oxobutyric acid.

24. The compound or salt of claim 21 , wherein the compound is ethyl 4-(4-(2-fluorobenzyloxyl)phenyl)-4-oxobutyrate.

25. The compound of claim 21 , ethyl 4-(3-(2-fluorobenzyloxyl)phenyl)-4-oxobutyrate.

26. The compound or salt of claim 15 , wherein R 2 is fluoro and R 3 is fluoro.

27. The compound or salt of claim 26 , wherein the compound is 4-(4-(2,5-difluorobenzyloxy)phenyl)-4-oxobutyric acid.

28. The compound or salt of claim 26 , wherein the compound is 4-(4-(2,4-difluorobenzyloxy)phenyl)-4-oxobutyric acid.

29. The compound of claim 26 , Ethyl 4-(4-(2,6-difluorobenzyloxy)phenyl)-3-oxobutyrate.

30. The compound or salt of claim 15 , wherein R 2 is methyl.

31. The compound or salt of claim 30 , wherein the compound is 4-(3-(2-Fluoro-6-methylbenzyloxy)phenyl)-4-oxobutyric acid.

32. The compound of claim 30 , Ethyl 4-(3-(2,6-dimethylbenzyloxyl)phenyl)-4-oxobutyrate.

33. The compound or salt of claim 30 , wherein the compound is 4-(4-(2,6-dimethylbenzyloxy)phenyl)-4-oxobutyric acid.

34. The compound of claim 26 , having the formula:

wherein

n is 1 or 2;

m is 0;

R 1 is H or alkyl having from 1 to 7 carbon atoms;

or when R 1 is hydrogen, a pharmaceutically acceptable salt of the compound.

35. The compound or salt of claim 34 , wherein the compound is 4-(4-(2,6-difluorobenzyloxy)phenyl)-4-oxobutyric acid.

36. The compound of claim 34 , Ethyl 4-(4-(2,6-difluorobenzyloxyl)phenyl)-4-oxobutyrate.

37. The compound or salt of claim 34 , wherein the compound is 4-(3-(2,6-difluorobenzyloxy)phenyl)-4-oxobutyric acid.

38. The compound or salt of claim 34 , wherein the compound is 4-(2-(2,6-difluorobenzyloxy)phenyl)-4-oxobutyric acid.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 055056/0891 →
SECURITY AGREEMENT Recorded Sep 18, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0227 →
SECURITY AGREEMENT Recorded Aug 16, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031029/0875 →